BergenBio Fundamentale Forhold (BGBIO)

HBS · desember 8, 2020, 4:04pm

Har du noen kilde på det??

eiken · desember 8, 2020, 4:43pm

Produsentene sier dette selv. Har ikke fremsatt lengde på immunitet av andre vaksine og hvor mange som tåles å gi.

Hfyh · desember 8, 2020, 5:45pm

Har lest dette jeg og, at 3 dose må gis 3 måneder etter dose 2, men tror det bare var 1 av produsentene.

TekBot · desember 9, 2020, 6:01am

BerGenBio ASA: Extraordinary General Meeting today

Bergen, Norway, 9 December 2020 - Extraordinary General Meeting in BerGenBio ASA
is being held virtually today 9 December 2020 at 16:00 hours (CET).

…

Vis børsmeldingen

Information on how to join the meeting:

Webcast link: https://web.lumiagm.com/?fromUrl=127403163

Meeting ID: 127-403-163

Please note you must be logged in online before the meeting starts to be able to
vote on issues on the agenda. You will then be required to enter your ID: a)
reference number from VPS and b) PIN code from VPS

Guide for online participation can be found at www.bergenbio.com under Investors
/ General meetings

-Ends-

For further information, please contact:

Richard Godfrey CEO, BerGenBio ASA
+47 917 86 304

Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com
+47 917 86 513

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

Biotec · desember 9, 2020, 6:04am

Hva gjelder denne?

Saltimaten · desember 9, 2020, 6:16am

Utskiftinger i styret, om jeg husker rett.

TekBot · desember 9, 2020, 4:35pm

BERGENBIO ASA: EXTRAORDINARY GENERAL MEETING

Bergen, Norway, 9 December 2020 - Extraordinary General Meeting in
BerGenBio ASA was held virtually on 9 December 2020 at 16:00 hours (CET).

…

Vis børsmeldingen

All proposals were resolved as presented in the notice convening the
extraordinary general meeting distributed on 18 November 2020, as further set
out in the minutes from the extraordinary general meeting attached hereto
and available at https://www.bergenbio.com/investors/general-
meetings/ (https://www.bergenbio.com/investors/general-%20meetings/)

-Ends-

For further information, please contact:

Richard Godfrey CEO, BerGenBio ASA
+47 917 86?304

Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com
+47 917 86?513

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

TekBot · desember 16, 2020, 4:01pm

BERGENBIO TO PRESENT AN UPDATE ON THE ONGOING PHASE II STUDY OF BEMCENTINIB IN COMBINATION WITH PEMBROLIZUMAB IN REFRACTORY NSCLC AT WCLC 2020

Bergen, Norway, 16 December 2020 - BerGenBio ASA (OSE:BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL kinase inhibitors for
severe unmet medical need, is pleased to announce it has been accepted for an
…

Vis børsmeldingen

oral presentation at the 2020 World Conference on Lung Cancer Singapore (WCLC),
being held from 28-31 January 2021.

The oral presentation will provide an update from the Company’s Phase II study
of bemcentinib in combination with anti-PD-1 therapy pembrolizumab (BGBC008) in
refractory non-small cell lung cancer (NSCLC).

Abstract titles have been announced online, and details of the presentation are
below.

Title: A phase II study of the oral selective AXL inhibitor bemcentinib with
pembrolizumab in patients with advanced NSCLC

Presenting Author: Dr. Matthew G. Krebs PhD.

Session/Abstract ID: Immunotherapy (Phase II/III Trials) / # 3647

Date/Time: Friday 29[th] January 2021 at 09.50 Singapore Time / 02.50 CET

Further details can be found on the WCLC
website (https://library.iaslc.org/conference
-program?product_id=20&author=&category=&date=&session_type=&session=&presentatio
n=&keyword=bemcentinib&cme=undefined&)

The presentation will be available on BerGenBio’s website from 29 January 2021.

END -

About AXL

AXL kinase is a cell membrane receptor and an essential mediator of the
biological mechanisms underlying life-threatening diseases. In cancer, AXL
suppresses the body’s immune response to tumours and drives cancer treatment
failure across many indications. AXL expression defines a very poor prognosis
subgroup in most cancers. AXL inhibitors, therefore, have potential high value
at the centre of cancer combination therapy, addressing significant unmet
medical needs and multiple high-value market opportunities. Research has also
shown that AXL mediates other aggressive diseases.

About Bemcentinib

Bemcentinib (formerly known as BGB324), is a potentially first-in-class
selective AXL inhibitor in a broad phase II clinical development programme.
Ongoing clinical trials are investigating bemcentinib in multiple solid and
haematological tumours, in combination with current and emerging therapies
(including immunotherapies, targeted therapies and chemotherapy), and as a
single agent. Bemcentinib targets and binds to the intracellular catalytic
kinase domain of AXL receptor tyrosine kinase and inhibits its activity.
Increase in AXL function has been linked to key mechanisms of drug resistance
and immune escape by tumour cells, leading to aggressive metastatic cancers.

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including immune-evasive, therapy resistant cancers. The
company’s proprietary lead candidate, bemcentinib, is a potentially first-in
-class selective AXL inhibitor in a broad phase II oncology clinical development
programme focused on combination and single agent therapy in lung cancer,
leukaemia and COVID-19. A first-in-class functional blocking anti-AXL antibody,
tilvestamab, is undergoing phase I clinical testing. In parallel, BerGenBio is
developing companion diagnostic tests to identify patient populations most
likely to benefit from bemcentinib: this is expected to facilitate more
efficient registration trials supporting a precision medicine-based
commercialisation strategy.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit www.bergenbio.com

Contacts

Richard Godfrey CEO, BerGenBio ASA
+47 917 86 304

Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com
+47 917 86 513

International Media Relations

Mary-Jane Elliott, Chris Welsh, Lucy Featherstone, Carina Jurs

Consilium Strategic Communications
bergenbio@consilium-comms.com
+44 20 3709 5700

Media Relations in Norway

Jan Petter Stiff, Crux Advisers

stiff@crux.no
+47 995 13 891

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

Ekornet · desember 16, 2020, 4:04pm

Er så latterlig bra!

TekBot · desember 16, 2020, 4:39pm

Flaggemelding - BGBIO

Flottesen · desember 16, 2020, 6:26pm

Statens Direkte Økonomiske Engasjement, avdeling biotek?

drdr · desember 16, 2020, 6:29pm

Spekulasjon eller fakta?

Flottesen · desember 16, 2020, 6:32pm

Det var en spøk, staten har lenge vært nest største eier i BGBIO via Investinor, statens eget venture investerinsselskap. Underselskapet Investinor Direkte ga meg assosiasjoner til SDØE.

alfred_e_neuman · desember 23, 2020, 10:23pm

MicroRNA 34a–AXL Axis Regulates Vasculogenic Mimicry Formation in Breast Cancer Cells

Received: 13 November 2020 / Accepted: 18 December 2020 / Published: 23 December 2020
https://www.mdpi.com/2073-4425/12/1/9 (DOI)

Vasculogenic mimicry (VM) refers to the formation of vessel-like structures by tumor cells, which can contribute to tumor neovascularization, and is closely related to metastasis and a poor prognosis. Here, we report a novel function of AXL receptor tyrosine kinase (AXL) in the regulation of VM formation in breast cancer cells. MDA-MB-231 cells exhibited VM formation on Matrigel cultures, whereas MCF-7 cells did not. Moreover, AXL expression was positively correlated with VM formation. Pharmacological inhibition or AXL knockdown strongly suppressed VM formation in MDA-MB-231 cells, whereas the overexpression of AXL in MCF-7 cells promoted VM formation. […] These results identify a miR-34a–AXL axis that is critical for the regulation of VM formation and may serve as a therapeutic target to inhibit tumor neovascularization.

To further investigate the role of AXL in VM formation, MDA-MB-231 breast cancer cells were treated with varying concentrations of R428, an AXL inhibitor, and its effects on VM formation were observed. All concentrations of R428 significantly inhibited VM formation (Figure 2D). Altogether, AXL inhibition was sufficient to abolish VM formation ability, suggesting the important role of AXL in this process.

We found that AXL knockdown caused a significant decrease in the invasion and migration of MDA-MB-231 breast cancer cells (Figure 3A,B). In addition, AXL inhibition by R428 decreased the motility of MDA-MB-231 cells (Figure 3C). These results suggest AXL is associated with invasiveness and VM ability of MDA-MB- 231 cells.

In conclusion, we show that the modulation of AXL expression via miR-34a can manipulate VM formation and aggressiveness in breast cancer cells. These findings provide a basis for overcoming the limitations of existing cancer therapies and developing new therapies.

(Bemcentinib, also known as BGB324 or R428)

Tekspert · januar 1, 2021, 10:00am

Hver måned kårer jeg det jeg kaller Teksperter™ for noen av de mest populære investeringene våre

Det er de 3 medlemmene som har fått flest likes på innleggene sine de siste 90 dagene. Teksperter™ får også en unikt merke på profilen sin og et trofé-ikon ved siden av navnet sitt. Du kan bli Tekspert™ i flere aksjer/investeringer, og troféet vil bare vises i tråder der du er Tekspert™.

Her er denne månedens Teksperter™ og det mest likte innlegget deres fra de siste 90 dagene:

@Mykle (242 likes)

@HeldigFyr (129 likes)

@BioMed (115 likes)

Resten av topp 10:

@BillyP (112 likes)
@eiken (111 likes)
@Londonmannen (102 likes)
@alfred_e_neuman (101 likes)
@Savepig (98 likes)
@Ekornet (92 likes)
@Hfyh (90 likes)

Gratulerer!

TekBot · januar 11, 2021, 6:01am

DATA MONITORING COMMITTEE RECOMMENDS CONTINUATION OF BERGENBIO’S BGBC020 TRIAL ASSESSING BEMCENTINIB IN COVID-19 PATIENTS

Bergen, Norway, 11[th] January 2021 - BerGenBio ASA (OSE:BGBIO), a clinical
-stage biopharmaceutical company developing novel, selective AXL kinase
inhibitors for severe unmet medical need, provides an update on the Company
…

Vis børsmeldingen

sponsored Phase II clinical trial (BGBC020), assessing the efficacy and safety
of bemcentinib for the treatment of hospitalised COVID-19 patients in South
Africa and India, following a meeting of the trial’s independent Data Monitoring
Committee (iDMC).

The iDMC, formed from a group of independent infectious disease clinical experts
external to the study, has recommended that the trial should continue as planned
with no changes, as no safety concerns were raised from the available data. The
iDMC will continue to assess the safety data and critical efficacy endpoints
of the trial, as it progresses.

The Phase II BGBC020 study will recruit 120 hospitalised COVID-19 patients
across five sites in South Africa and seven sites in India. 60 patients will
receive bemcentinib (as monotherapy or in combination with standard of care
treatment) and 60 patients in a control group (receiving standard of care
treatment only).

The primary endpoint of the trial will be time to clinical improvement of at
least two points (from randomisation) on a nine-point ordinal scale, or live
discharge from the hospital, whichever comes first. The trial protocol will
permit co-administration with other medicines recommended for treatment of COVID
-19, including remdesivir and dexamethasone.

Richard Godfrey, Chief Executive Officer of BerGenBio, commented: “We continue
to have confidence in the favourable safety profile of bemcentinib, and are
pleased that the iDMC has recommended the continuation of the BGBC020 trial. We
look forward to recording further data. We are hopeful that bemcentinib can play
a role in the global effort to find an effective treatment option for
hospitalised COVID-19 patients, particularly as we continue to see an increase
in incidence of the virus in many areas of the world.”

END -

About AXL

AXL kinase is a cell membrane receptor and an essential mediator of the
biological mechanisms underlying life-threatening diseases. In cancer, AXL
suppresses the body’s immune response to tumours and drives cancer treatment
failure across many indications. AXL expression defines a very poor prognosis
subgroup in most cancers. AXL inhibitors, therefore, have potential high value
at the centre of cancer combination therapy, addressing significant unmet
medical needs and multiple high-value market opportunities. Research has also
shown that AXL mediates other aggressive diseases.

About Bemcentinib

Bemcentinib (formerly known as BGB324), is a potentially first-in-class
selective AXL inhibitor in a broad phase II clinical development programme.
Ongoing clinical trials are investigating bemcentinib in multiple solid and
haematological tumours, in combination with current and emerging therapies
(including immunotherapies, targeted therapies and chemotherapy), and as a
single agent. Bemcentinib targets and binds to the intracellular catalytic
kinase domain of AXL receptor tyrosine kinase and inhibits its activity.
Increase in AXL function has been linked to key mechanisms of drug resistance
and immune escape by tumour cells, leading to aggressive metastatic cancers.

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including immune-evasive, therapy resistant cancers. The
company’s proprietary lead candidate, bemcentinib, is a potentially first-in
-class selective AXL inhibitor in a broad phase II oncology clinical development
programme focused on combination and single agent therapy in lung cancer,
leukaemia and COVID-19. A first-in-class functional blocking anti-AXL antibody,
tilvestamab, is undergoing phase I clinical testing. In parallel, BerGenBio is
developing companion diagnostic tests to identify patient populations most
likely to benefit from bemcentinib: this is expected to facilitate more
efficient registration trials supporting a precision medicine-based
commercialisation strategy.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit www.bergenbio.com

Contacts

Richard Godfrey CEO, BerGenBio ASA
+47 917 86 304

Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com
+47 917 86 513

International Media Relations

Mary-Jane Elliott, Chris Welsh, Lucy Featherstone, Carina Jurs

Consilium Strategic Communications
bergenbio@consilium-comms.com
+44 20 3709 5700

Media Relations in Norway

Jan Petter Stiff, Crux Advisers

stiff@crux.no
+47 995 13 891

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

Halling · januar 11, 2021, 6:11am

Dette var gode nyheter på en mandags morgen. Som flere her inne har påpekt før, de hadde stoppet denne studien viss de ikke hadde sett forbedring hos pasientene.

TyrionIV · januar 11, 2021, 6:15am

Det eneste man kan lese ut av denne mld er at safety ser ok ut foreløpig…

HBS · januar 11, 2021, 6:29am

Enig - dette visste vi, ser meldingen som helt neutral. Men hva kan vi ellers lese ut av meldingen her? Hvor mange pasienter pleier være inkludert i studier når SRC ser på data? 15%, 25%, 30% ?

anon99889496 · januar 11, 2021, 6:39am

No safety concerns er jo hva di fleste her har fått med seg, men fortsatt et bra stikk til dem som måtte tvile på det.